ThaiPR.NET https://www.thaipr.net/location/gaithersburg-md Press Release Distribution Center of Thailand Fri, 03 Apr 2026 17:33:14 +0700 hourly 1 https://wordpress.org/?v=6.1.1 <![CDATA[Novavax’s Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization]]> https://www.thaipr.net/en/health_en/3416365 Wed, 29 Nov 2023 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3416365 Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older. The EUL assists WHO member states in assessing vaccines […]

The post Novavax’s Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.]]> https://www.thaipr.net/en/health_en/3391668 Wed, 04 Oct 2023 08:40:12 +0700 health_en https://www.thaipr.net/en/health_en/3391668 Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older. Immediately upon authorization, Novavax’s vaccine has […]

The post Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. appeared first on ThaiPR.NET.

]]> <![CDATA[Positive Phase 2 Topline Results Show Novavax’s COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses]]> https://www.thaipr.net/en/health_en/3334303 Wed, 10 May 2023 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3334303 Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that its COVID-Influenza Combination (CIC), stand-alone influenza and high-dose COVID vaccine candidates all showed a reassuring preliminary safety profile as well as comparable reactogenicity to individual Novavax influenza and COVID vaccine candidates or authorized influenza vaccine comparators. Additionally, all […]

The post Positive Phase 2 Topline Results Show Novavax’s COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses appeared first on ThaiPR.NET.

]]> <![CDATA[U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax’ COVID-19 Vaccine]]> https://www.thaipr.net/en/health_en/3301485 Tue, 14 Feb 2023 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3301485 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a modification to its existing agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense, to deliver up to 1.5 million doses of the Novavax COVID-19 Vaccine, […]

The post U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax’ COVID-19 Vaccine appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax Announces Pricing of $65 Million Public Offering of Common Stock]]> https://www.thaipr.net/en/health_en/3281681 Fri, 16 Dec 2022 12:56:38 +0700 health_en https://www.thaipr.net/en/health_en/3281681 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of its common stock at a public offering price of $10.00 per share, or $65 million worth of shares of its common stock. In connection with the common stock offering, Novavax granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of its common […]

The post Novavax Announces Pricing of $65 Million Public Offering of Common Stock appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes]]> https://www.thaipr.net/en/general_en/3281680 Fri, 16 Dec 2022 12:45:30 +0700 general_en https://www.thaipr.net/en/general_en/3281680 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027 (the “notes”). The notes are being offered and sold only to persons reasonably believed to be qualified […]

The post Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes]]> https://www.thaipr.net/en/health_en/3281460 Fri, 16 Dec 2022 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3281460 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of $125 million aggregate principal amount of convertible senior notes due 2027 (the “notes”). The notes will be offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant […]

The post Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax Announces Proposed $125 Million Public Offering of Common Stock]]> https://www.thaipr.net/en/finance_en/3280863 Thu, 15 Dec 2022 08:43:24 +0700 finance_en https://www.thaipr.net/en/finance_en/3280863 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125 million of its common stock. In connection with the common stock offering, Novavax expects to grant to the underwriters a 30-day option to purchase up to an additional $18.75 million of its common stock at the public offering price, less underwriting discounts and commissions. J.P. Morgan, Jefferies and Cowen are acting […]

The post Novavax Announces Proposed $125 Million Public Offering of Common Stock appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster]]> https://www.thaipr.net/en/health_en/3263635 Wed, 09 Nov 2022 08:05:00 +0700 health_en https://www.thaipr.net/en/health_en/3263635 The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary Novavax’ prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains The trial showed no benefit for a bivalent vaccine utilizing Novavax’ recombinant protein/adjuvant technology Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to […]

The post Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster appeared first on ThaiPR.NET.

]]> <![CDATA[U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults]]> https://www.thaipr.net/en/health_en/3254291 Thu, 20 Oct 2022 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3254291 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a first booster dose at least six months after completion of primary vaccination […]

The post U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants]]> https://www.thaipr.net/en/health_en/3252111 Mon, 17 Oct 2022 08:10:00 +0700 health_en https://www.thaipr.net/en/health_en/3252111 Homologous boosting with the prototype Novavax COVID-19 vaccine induced robust antibody titers for Omicron BA.1, BA.2, and BA.5 Study 307 (Lot Consistency) achieved its primary endpoint, showing that three vaccine lots induced a comparable immune response thereby demonstrating the consistency of the manufacturing process A durable immunogenicity response was observed following primary vaccination as well […]

The post Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants appeared first on ThaiPR.NET.

]]> <![CDATA[U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17]]> https://www.thaipr.net/en/general_en/3227730 Mon, 22 Aug 2022 08:00:00 +0700 general_en https://www.thaipr.net/en/general_en/3227730 Novavax’ vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. Doses of the Novavax COVID-19 Vaccine, Adjuvanted are now available and primary series immunizations for adolescents can begin once a policy recommendation from the CDC is received Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious […]

The post U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17 appeared first on ThaiPR.NET.

]]> <![CDATA[U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older]]> https://www.thaipr.net/en/general_en/3214739 Wed, 20 Jul 2022 09:01:56 +0700 general_en https://www.thaipr.net/en/general_en/3214739 Recommendation follows U.S. FDA Emergency Use Authorization for the Novavax COVID-19 Vaccine, Adjuvanted as a two-dose primary series FDA has determined that first vaccine lot has met all release specifications and is acceptable for use under Emergency Use Authorization Novavax expects to ship doses to the U.S. Government-designated distribution center in the coming days Novavax’ vaccine is […]

The post U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older appeared first on ThaiPR.NET.

]]> <![CDATA[U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over]]> https://www.thaipr.net/en/health_en/3212765 Thu, 14 Jul 2022 09:45:15 +0700 health_en https://www.thaipr.net/en/general_en/3212765 Novavax’ vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. Immunizations with the Novavax COVID-19 Vaccine, Adjuvanted as a primary series will begin upon product release and once a policy recommendation from the CDC is received Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, […]

The post U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over appeared first on ThaiPR.NET.

]]> <![CDATA[U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine]]> https://www.thaipr.net/en/general_en/3212152 Tue, 12 Jul 2022 08:00:00 +0700 general_en https://www.thaipr.net/en/general_en/3212152 Agreement will provide the first protein-based vaccine option in the U.S., pending FDA Emergency Use Authorization and CDC recommendation Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced an agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department […]

The post U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17]]> https://www.thaipr.net/en/general_en/3210133 Wed, 06 Jul 2022 08:45:00 +0700 general_en https://www.thaipr.net/en/general_en/3210133 Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in the […]

The post Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17 appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17]]> https://www.thaipr.net/en/general_en/3205878 Fri, 24 Jun 2022 09:03:54 +0700 general_en https://www.thaipr.net/en/general_en/3205878 Upon authorization, Nuvaxovid™ would be the first protein-based option for adolescents aged 12 through 17 in Europe Nuvaxovid™ demonstrated 80% efficacy and was generally well-tolerated in adolescents Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional […]

The post Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17 appeared first on ThaiPR.NET.

]]> <![CDATA[FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older]]> https://www.thaipr.net/en/health_en/3199138 Wed, 08 Jun 2022 08:43:33 +0700 health_en https://www.thaipr.net/en/health_en/3199138 Novavax COVID-19 vaccine receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee If Emergency Use Authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the first protein-based COVID-19 vaccine available in the U.S. Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing […]

The post FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older appeared first on ThaiPR.NET.

]]> <![CDATA[Initial Results from Novavax’ COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine]]> https://www.thaipr.net/en/general_en/3181648 Thu, 21 Apr 2022 09:05:00 +0700 general_en https://www.thaipr.net/en/general_en/3181648 Phase 1/2 clinical trial of COVID-19-Influenza combination vaccine candidate indicates vaccine is well-tolerated and immunogenic Data from this combination trial will inform planned Phase 2 dose confirmation trial, scheduled to begin by the end of 2022 Immune response confirmed in stand-alone influenza vaccine and combination vaccine with potential path forward for both Novavax, Inc. (Nasdaq: NVAX), […]

The post Initial Results from Novavax’ COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan]]> https://www.thaipr.net/en/general_en/3181103 Wed, 20 Apr 2022 09:15:00 +0700 general_en https://www.thaipr.net/en/general_en/3181103 Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adults aged 18 and older in Japan Approval is first in the world for NVX-CoV2373 that includes both primary and booster vaccination Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that its partner, […]

The post Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan appeared first on ThaiPR.NET.

]]>